• Share
  • Email
  • Print

Haniya H. Mir

Associate
+1.919.743.7344
Fax +1.919.516.2067
Haniya Mir is an associate in the Raleigh office and primarily focuses her practice on securities, mergers and acquisitions, corporate governance and general corporate matters. She regularly advises clients on securities, transactional and corporate governance matters, including public and private securities offerings, mergers and acquisitions, and reporting requirements under the Securities Exchange Act of 1934 and compliance with stock exchange rules. Her experience includes advising companies on business formation and general corporate governance and compliance matters.

Professional Background

Ms. Mir was a summer associate at K&L Gates in 2014. She was a summer law clerk for the Office of Counsel at Duke University and Duke University Health System, Inc. in 2013. Before attending law school, Ms. Mir worked as a corporate paralegal in the New York, London, and Menlo Park offices of an international law firm.

Professional/Civic Activities

  • Duke University School of Law, Law Alumni Association, Board of Directors
  • Big Brothers Big Sisters of the Triangle - Emerging Leaders Board Member
  • North Carolina Bar Association
Securities and Capital Markets
  • Represented Nasdaq-listed molecular diagnostics company focused on colorectal cancer screening technology in connection with multiple underwritten public offerings of common stock as well as convertible bond offerings exceeding $1 billion.
  • Represented Nasdaq-listed ultrasound technology company in connection with an underwritten public offering of common stock.
  • Represented immunotherapy company in connection with its initial public offering and listing on the Nasdaq Capital Market.
  • Represented ultrasound technology company in connection with its initial public offering and listing on the Nasdaq Capital Market.
  • Regularly represents a variety of public companies in connection with periodic filings with the Securities and Exchange Commission and compliance with stock exchange rules.
Mergers & Acquisitions
  • Represented Nasdaq-listed molecular diagnostics company in its acquisition of a leading provider of biological sample preservation.
  • Represented Nasdaq-listed molecular diagnostics company in its acquisition of assets of a cancer diagnostics company.
  • Represented Nasdaq-listed molecular diagnostics company in its acquisition of a healthcare information technology company.
  • Represented Nasdaq-listed biotechnology company in connection with its cash acquisition by a leading global biotechnology and life science company.
  • Represented an oncology supportive care pharmaceutical company in connection with its acquisition by an international specialty pharmaceutical company.